Eczema drug Tralokinumab's eye risks under the microscope

NCT ID NCT05682976

Completed Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 100 adults with atopic dermatitis (eczema) who were prescribed tralokinumab. Researchers tracked how many developed eye problems like conjunctivitis within 4 months of starting the drug. The goal was to better understand these side effects in real-world use, not to test if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tralokinumab
What this could lead to: If successful, this study could help doctors better understand and manage eye side effects of tralokinumab, improving treatment safety for eczema patients.
What could go wrong: This is a small, completed observational study (100 participants) that only tracks side effects, not treatment effectiveness. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema conjunctivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

CHRU de Lille

Lille, France
CHU de Bordeaux

Bordeaux, France
CHU de Brest

Brest, France
CHU de Clermont Ferrand

Clermont-Ferrand, France
CHU de Nantes

Nantes, France
CHU de Rouen

Rouen, France
CHu de Dijon

Dijon, France
CHu de Poitiers

Poitiers, France
CHu de Rennes

Rennes, France
Hospice Civil de Lyon

Lyon, France
Hôpital Saint Louis

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.